All the news Showing 10 of 14 articles from: Treatment for previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources ‘Real-world’ studies in Germany and the USA confirm high rates of sustained virological response with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in individuals with chronic HCV infection failing DAAs EASL / 12 April 2019 Antiviral resistance testing in the management of hepatitis C Public Health England / 17 December 2018 Early Access to Medicines Scheme (EAMS) Granted to AbbVie’s Investigational Pan-genotypic Regimen for Chronic Hepatitis C in UK AbbVie press release / 10 May 2017 Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C Merck press release / 24 April 2017 Next-generation HCV treatments should benefit challenging patient groups Digestive Disease Week blog / 23 May 2016 Stefan Zeuzem: How I Manage HCV Patients for Whom First-Generation Protease Inhibitors Failed Clinical Care Options (requires registration) / 28 May 2014 Physicians are Foregoing Treatment of Their HCV Patients Until New Agents Become Available BioTrends / 06 August 2013 Boceprevir benefits null, partial responders to prior HCV therapy with peginterferon/ribavirin Healio Hepatology / 12 June 2013 Daclatasvir/asunaprevir effective in difficult-to-treat HCV populations Healio Hepatology / 09 April 2013 Telaprevir shows promise in black patients with genotype 1 HCV Healio / 12 March 2013 ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive